Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1469-8137.2007.02199.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction to: Infection's Association With Decreased Risk of Breast Cancer.
World J Oncol
December 2024
Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, FL, USA.
[This corrects the article DOI: 10.14740/wjon1617.].
View Article and Find Full Text PDFBackground: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. Here we present the final 10-year analysis of the ALTTO trial.
Patients And Methods: The ALTTO trial (NCT00490139) is a prospective randomized, phase III, open-label, multicenter study that investigated the role of adjuvant chemotherapy and trastuzumab alone, in combination or sequentially with lapatinib.
Article Synopsis
- * Recent efforts to stop smoking haven't been put into action yet, and it’s important to see what could happen if smoking rates stay the same or improve.
- * Researchers used models to predict health outcomes by 2050 based on different scenarios of smoking rates, showing that cutting smoking could greatly improve health and life expectancy.
Cannabis-related information sources among US residents: A probability-weighted nationally representative survey.
J Cannabis Res
October 2024
Michigan Psychedelic Center, University of Michigan Medical School, Ann Arbor, MI, USA.
Introduction: The Department of Health and Human Services recently recommended rescheduling cannabis from Schedule I to Schedule III, which might have broad effects on public health outcomes related to cannabis. In this changing environment, understanding national patterns in how people obtain information about cannabis is critical to informing public health outreach and education.
Methods: We surveyed American adults (≥ 18 years) between June 22nd-26th, 2023 using the AmeriSpeak panel.
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial.
J Am Coll Cardiol
November 2024
Weill Cornell Medicine, New York, New York, USA.
Background: Following an acute myocardial infarction (AMI), patients remain at risk for subsequent cardiovascular (CV) events. In the AEGIS-II trial, CSL112, a human apolipoprotein A-I derived from plasma that enhances cholesterol efflux, did not significantly reduce the first occurrence of CV death, myocardial infarction (MI), or stroke through 90 days compared with placebo. However, an analysis involving only the first event may not capture the totality of the clinical impact of an intervention because patients may experience multiple events.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!